Matthew Matasar
synapse.mskcc.org
0000-0002-4581-3721
Memorial Sloan Kettering Cancer Center
4 papers found
Refreshing results…
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Missing publications? Search for publications with a matching author name.